Clinical Trial Update: Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating induction with cisplatin/nab-paclitaxel/pembrolizumab followed by olaparib/pembrolizumab maintenance in metastatic t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN